ClinicalTrials.gg
Not yet recruitingNCT07945548Updated Nov 18, 2026

A Study Characterizing the Elevated Liver Enzymes in Ribociclib Treated HR+ HER2- Advanced Breast Cancer Patients Using a Machine Learning Approach With Real-world Data

An observational study in Breast Cancer, sponsored by Novartis Pharmaceuticals. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
8,001
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 200 studies in Breast Neoplasms by Novartis — 17 open to participants now, 31 under way, 4 of them phase 3. Breast Neoplasms · Novartis.

Planned enrollment
3rd of 39
8,001 · median 595
Started
2026
with 10 others
Observational
39 of 200
8 open now
Primary completion
2027-01
later than 1 of 30 live
Registered
200th of 200
by date

Among the 200 studies in Breast Neoplasms by Novartis, this one is the 3rd largest by planned enrollment of the 39 observational ones that give a count, is one of 11 that started in 2026, is one of 39 observational ones, reaches primary completion later than 1 of the 30 other live ones, and was the 200th registered.

Breast Neoplasms

14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

17 of the 200 studies in Breast Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Who these studies take

Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 200 studies in Breast Neoplasms by Novartis, or all of them as a file.
02

Study summary

The aim of this study is to assess key factors associated with response and non-response to the current established management algorithm for elevated liver enzymes (ELE) following ribociclib treatment in hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer (aBC) patients in real world settings in the United States (US). The data for this study will be drawn from a US-based breast cancer specific electronic health record (EHR) database.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Ribociclib
  • CDK4/6 inhibitor
  • Advanced breast cancer
  • Hormone receptor-positive
  • HR+
  • HER2-negative
  • HR+/HER2-
  • Elevated liver enzymes
  • Aspartate aminotransferase
  • AST
  • Alanine aminotransferase
  • ALT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients in the US with a diagnosis of HR+/HER2- aBC and evidence of ribociclib use.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Evidence of diagnosis of Stage IV breast cancer (aBC) as per American Joint Committee on Cancer (AJCC), 8th Edition during study period
  2. Aged 18 years or older at the index date
  3. Have at least one prescription for Ribociclib
  4. Have lab values available for /aspartate aminotransferase (ALT/AST) at baseline, and up to 6 months post-baseline (at least one measurement at baseline and one measurement during follow up)

Exclusion criteria

Exclusion criteria:

  1. Missing values for patient ID or age
  2. No available lab data for liver enzymes (/AST) at either baseline or up to 6 months post-baseline
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
8,001 participants (estimated)
Patient registry
No

Groups and cohorts

  • Ribociclib Treatment Responders

    Patients who undergo a management action (dose reduction or temporary suspension) and achieve recovery to ≤ baseline grade ALT/AST within 60 days without permanent treatment discontinuation or treatment switch.

  • Ribociclib Treatment Non-responders

    Patients who undergo a management action (dose reduction or temporary suspension) but whose ALT/AST level does not recover to baseline grade within 60 days, experience a worsening grade, recurrence after rechallenge, permanent treatment discontinuation or switch to another systemic therapy.

06

What researchers measure

Primary outcomes

  1. Among aBC Patients Who Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Number of Patients by Demographics and Clinical Characterisitcs

    Demographics and clinical characteristics include age group, sex, race, ethnicity, geographical location, insurance type, socioeconomic status (SES) index (1 = lowest SES, 2, 3, 4, 5 = highest SES), menopausal status, smoking status, year of breast cancer (BC) diagnosis, type of BC, biomarker status, Eastern Cooperative Oncology (ECOG) performance status (0 = fully active, 1, 2, 3, 4 = completely disabled) number of metastatic sites, site of metastasis, chemotherapy status, radiation status, surgery status, and comorbidities.

    Time frame: Baseline

  2. Among aBC Patients Who Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Age at Ribociclib Initiation

    Time frame: Baseline

  3. Among aBC Patients Who Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Duration of Follow-up

    Time frame: Up to approximately 12 months

  4. Among aBC Patients Who Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Body Weight

    Time frame: Baseline

  5. Among aBC Patients Who Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Charlson Comorbidity Index (CCI)

    CCI is a weighted index that takes into account both the number and the seriousness of comorbid conditions. Each condition is assigned a weighted score, and the scores are summed to generate a total CCI score. Total scores range from 0 to 37, with higher scores reflecting a greater burden of disease and an increased risk of mortality.

    Time frame: Baseline

Secondary outcomes

  1. Among aBC Patients Who do not Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Number of Patients by Demographics and Clinical Characterisitcs

    Demographics and clinical characteristics include age group, sex, race, ethnicity, geographical location, insurance type, SES index (1 = lowest SES, 2, 3, 4, 5 = highest SES), menopausal status, smoking status, year of BC diagnosis, type of BC, biomarker status, ECOG performance status (0 = fully active, 1, 2, 3, 4 = completely disabled) number of metastatic sites, site of metastasis, chemotherapy status, radiation status, surgery status, and comorbidities.

    Time frame: Baseline

  2. Among aBC Patients Who do not Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Age at Ribociclib Initiation

    Time frame: Baseline

  3. Among aBC Patients Who do not Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Duration of Follow-up

    Time frame: Up to approximately 12 months

  4. Among aBC Patients Who do not Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Body Weight

    Time frame: Baseline

  5. Among aBC Patients Who do not Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, CCI

    Time frame: Baseline

  6. Among aBC Patients Who Experience a First ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Number of Patients With Subsequent Episodes of ALT/AST Elevation

    Time frame: Up to approximately 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Jan 2027, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Nov 13, 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945548
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Nov 13, 2026 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion